ERBB2 and neoplasm: Other authors determined HER2 heterogeneity by deviating HER2 status in a set of primary biopsies (Kaito et al. 2019), of resection specimen (Xu et al. 2019) or in paired specimens from the primary tumor and metastasis (Peng et al. 2015).